2022
Emerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma
Crane J, Shi Q, Xi Y, Lai J, Pham K, Wang H. Emerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma. Journal Of Clinical And Translational Pathology 2022, 2: 31-36. PMID: 36275841, PMCID: PMC9585478, DOI: 10.14218/jctp.2022.00004.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaCell carcinomaHuman papillomavirusHuman papillomavirus-positive oropharyngeal squamous cell carcinomaHPV-positive oropharyngeal squamous cell carcinomaHPV-negative oropharyngeal squamous cell carcinomaActive human papillomavirusNew targetsLong-term survivalPotential new targetsDefinitive treatmentHPV 16Treatment optionsSurvival prognosisTumor prognosisAdvanced stageHealth responsePrecision treatmentPrecision medicinePatientsCarcinomaPrognosisTreatmentPathological research
2020
Classify multicategory outcome in patients with lung adenocarcinoma using clinical, transcriptomic and clinico-transcriptomic data: machine learning versus multinomial models.
Deng F, Shen L, Wang H, Zhang L. Classify multicategory outcome in patients with lung adenocarcinoma using clinical, transcriptomic and clinico-transcriptomic data: machine learning versus multinomial models. American Journal Of Cancer Research 2020, 10: 4624-4639. PMID: 33415023, PMCID: PMC7783755.Peer-Reviewed Original ResearchCytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico
Jiang Z, Sun X, Wu Z, Alhatem A, Zheng R, Liu D, Wang Y, Kumar D, Xia C, You B, Wang H, Liu C, Jiang JG. Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico. Oncotarget 2020, 11: 4411-4420. PMID: 33315966, PMCID: PMC7720771, DOI: 10.18632/oncotarget.27824.Peer-Reviewed Original ResearchCMML patientsChronic myelomonocytic leukemiaFavorable prognosisClinical significanceMolecular landscapePossible clinical significancePotential clinical significanceClonal hematopoietic neoplasmsMyeloproliferative characteristicsUnfavorable prognosisPathological featuresMyelomonocytic leukemiaPatientsTrisomy 8Abnormal karyotypeCytogenetic abnormalitiesHematopoietic neoplasmsPrognosisRacial disparitiesGene mutationsLower ratesHigh rateProfile testPuerto RicoPrevious studies
2018
Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema
Cornwell WD, Kim C, Lastra AC, Dass C, Bolla S, Wang H, Zhao H, Ramsey FV, Marchetti N, Rogers TJ, Criner GJ. Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema. Biomarkers 2018, 24: 232-239. PMID: 30411980, PMCID: PMC6509019, DOI: 10.1080/1354750x.2018.1542458.Peer-Reviewed Original ResearchConceptsInterstitial pulmonary fibrosisInflammatory profilePulmonary fibrosisLung tissueInflammatory proteinDistinct inflammatory profilesCohort of patientsCombined pulmonary fibrosisDistinct inflammatory processesEmphysematous lung tissueInflammatory protein levelsExplanted LungsInflammatory signatureInflammatory processDisease processEmphysemaPatientsEmphysematous tissueFibrosisLungProtein levelsTissue sectionsCPFETissueTissue extracts
2017
Clinically isolated aortitis: pitfalls, progress, and possibilities
Cinar I, Wang H, Stone J. Clinically isolated aortitis: pitfalls, progress, and possibilities. Cardiovascular Pathology 2017, 29: 23-32. PMID: 28500877, DOI: 10.1016/j.carpath.2017.04.003.Peer-Reviewed Original ResearchConceptsGiant cell arteritisExtracranial giant cell arteritisNon-infectious aortitisSubsequent aortic eventsSystemic rheumatologic diseaseComputed tomography scanningMagnetic resonance imagingPositron emission tomographyGiant cell patternAortic eventsImmunosuppressive therapyInfectious aortitisSystemic vasculitisCell arteritisRheumatologic diseasesClinical evidenceSystemic disordersAortic imagingAortitisAortic tissuePatientsResonance imagingTomography scanningEmission tomographyMultiple studies
2014
Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy
JIANG H, WANG H, WANG S, PEI Z, FU Z, FANG C, WANG J, LU Q, WANG E, LI J. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy. Molecular Medicine Reports 2014, 11: 3523-3532. PMID: 25573098, DOI: 10.3892/mmr.2014.3141.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDNA-Binding ProteinsDrug Resistance, NeoplasmEndonucleasesFemaleGene ExpressionHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMyoD ProteinMyoglobinMyosin Type IIPlatinumPleural Effusion, MalignantPrognosisRibonucleoside Diphosphate ReductaseThymidylate SynthaseTubulinTumor Suppressor ProteinsConceptsExcision repair cross-complementing gene 1Expression of ERCC1Platinum-based chemotherapyMetastatic lung adenocarcinomaLung adenocarcinomaPleural effusionLung Adenocarcinoma Pleural EffusionsPlatinum-based chemotherapy treatmentTumor cellsUntreated lung adenocarcinomasSurvival of patientsMalignant pleural effusionPleural fluid samplesExpression levelsProtein expression levelsWestern blot analysisClinical outcomesPatient survivalLung cancerChemotherapy treatmentLung carcinomaNon-muscle myosin IIPatientsAdenocarcinomaSurvival rate